ClinicalTrials.gg
CompletedNCT05673889Updated Aug 16, 2024Results posted

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

A Phase 1 interventional study of ARV-471 and Dabigatran etexilate in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to understand if ARV-471 affects how a medicine called, dabigatran etexilate, gets absorbed or processed into the body in healthy adults.

All participants in this study will receive one dose of dabigatran etexilate alone by mouth in Period 1. In Period 2, everyone will receive one dose of dabigatran etexilate by mouth approximately 90 minutes after receiving one dose of ARV-471 by mouth. The levels of dabigatran in Period 1 will be compared to the levels of dabigatran in Period 2. This will help us to determine if and how ARV-471 affects dabigatran gets absorbed into the body differently in healthy adults.

All participants will stay at the study clinic for approximately 8 days and 7 nights.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female participants of non- who are overtly healthy as determined by medical evaluation and are between the ages of 18 and 70 years, inclusive at the time of signing the document (ICD).
  • (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight >50 kg (110 lb).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Pregnant female participants, breastfeeding female participants, female participants of . Male participants with partners currently pregnant; male participants of childbearing potential who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for 90 days after the last dose of product.
  • Active bleeding or risk of bleeding including prior personal or familiar history of abnormal bleeding, hereditary or acquired coagulation or disorder or abnormal coagulation test ( or PTT/aPTT greater than ) result at screening. Any significant risk factor for major bleeding and this may include but not limited to current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, or other conditions or situations related to COVID-19 pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of prescription or nonprescription medications, including vitamins, dietary and herbal supplements, grapefruit/grapefruit containing products, and Seville orange/Seville orange containing products within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention or a longer is required for those that fall into the categories below:

    • Moderate or strong cytochrome P450 (CYP) 3A / P-glycoprotein (P-gp) inducers which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.
    • Moderate or strong /P-gp inhibitors which are prohibited within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • Standard 12-lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate with and without ARV-471

    Dabigatran etexilate administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.

    Drug: ARV-471 · Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With ARV-471

    Cmax was defined as maximum observed plasma concentration. Cmax for total dabigatran was observed directly from data.

    Time frame: Period 1 and 2: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on Day 1

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Total Dabigatran When Dabigatran Etexilate is Administered Alone vs Dabigatran Etexilate is Administered With ARV-471

    AUCinf was defined as area under the concentration-time curve from time 0 extrapolated to infinity. AUCinf was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve; AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

    Time frame: Period 1 and 2: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on Day 1

Secondary outcomes

  1. Number of Participants With All-Causality and Treatment-Related Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

    Time frame: From the first dose (Day 1) up to 35 days after the last dose (Day 5) of study intervention (up to 40 days)

  2. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day -1) up to Period 2 Day 3 (8 days)

  3. Number of Participants With Clinically Significant Vital Signs

    Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 3 (7 days)

  4. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by \>60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value \>500 ms for any scheduled ECG.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 3 (7 days)

07

Results

Posted Aug 16, 2024

Participant flow

Period 1 (4 Days)
Participant flow — Period 1 (4 Days)
MilestoneAll Participants
Started24
Completed24
Not completed0
Period 2 (3 Days)
Participant flow — Period 2 (3 Days)
MilestoneAll Participants
Started24
Completed24
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With ARV-471

Cmax was defined as maximum observed plasma concentration. Cmax for total dabigatran was observed directly from data.

Time frame:
Period 1 and 2: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With ARV-471
nanogram per milliliter (ng/mL)Period 1: Dabigatran 75 mgPeriod 2: Dabigatran 75 mg + ARV-471 200 mg
Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With ARV-47149.80 ± 9495.72 ± 66
Statistical analysis
  • Period 1: Dabigatran 75 mg vs Period 2: Dabigatran 75 mg + ARV-471 200 mg · Ratio (%) of adjusted geometric means: 192.20 · 90% CI 166.56 to 221.79The ratios (and 90% CIs) are expressed as percentages.
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Total Dabigatran When Dabigatran Etexilate is Administered Alone vs Dabigatran Etexilate is Administered With ARV-471

AUCinf was defined as area under the concentration-time curve from time 0 extrapolated to infinity. AUCinf was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve; AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

Time frame:
Period 1 and 2: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Total Dabigatran When Dabigatran Etexilate is Administered Alone vs Dabigatran Etexilate is Administered With ARV-471
nanogram*hour per milliliter (ng*hr/mL)Period 1: Dabigatran 75 mgPeriod 2: Dabigatran 75 mg + ARV-471 200 mg
Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Total Dabigatran When Dabigatran Etexilate is Administered Alone vs Dabigatran Etexilate is Administered With ARV-471522.3 ± 42949.6 ± 63
Statistical analysis
  • Period 1: Dabigatran 75 mg vs Period 2: Dabigatran 75 mg + ARV-471 200 mg · Ratio (%) of adjusted geometric means: 197.81 · 90% CI 177.32 to 220.66The ratios (and 90% CIs) are expressed as percentages.
SecondaryNumber of Participants With All-Causality and Treatment-Related Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

Time frame:
From the first dose (Day 1) up to 35 days after the last dose (Day 5) of study intervention (up to 40 days)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality and Treatment-Related Treatment-emergent Adverse Events (TEAEs)
ParticipantsDabigatran 75 mgDabigatran 75 mg + ARV-471 200 mg
Participants with all-causality TEAEs66
Participants with all-causality SAEs00
Participants with treatment related TEAEs31
Participants with treatment related SAEs00
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day -1) up to Period 2 Day 3 (8 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsDabigatran 75 mgDabigatran 75 mg + ARV-471 200 mg
Monocytes/Leukocytes (%) >1.2 × ULN22
Leukocyte Esterase >=101
SecondaryNumber of Participants With Clinically Significant Vital Signs

Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 3 (7 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs
ParticipantsDabigatran 75 mgDabigatran 75 mg + ARV-471 200 mg
Number of Participants With Clinically Significant Vital Signs00
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by \>60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value \>500 ms for any scheduled ECG.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 3 (7 days)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsDabigatran 75 mgDabigatran 75 mg + ARV-471 200 mg
Number of Participants With Electrocardiogram (ECG) Abnormalities12

Adverse events

Collected over From the first dose (Day 1) up to 35 days after the last dose (Day 5) of study intervention (up to 40 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Dabigatran 75 mg0/24 (0%)0/24 (0%)2/24 (8.3%)
Period 2: Dabigatran 75 mg + ARV-471 200 mg0/24 (0%)0/24 (0%)2/24 (8.3%)
Most frequent other events
Most frequent other events
EventPeriod 1: Dabigatran 75 mgPeriod 2: Dabigatran 75 mg + ARV-471 200 mg
ContusionInjury, poisoning and procedural complications0/242/24
HaematomaVascular disorders2/240/24

Baseline characteristics

The baseline analysis population was defined as all participants enrolled and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)All Participants
Mean44.7 ± 15.92
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female4
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino2
Not Hispanic or Latino22
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White19
Black or African American4
Asian1
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2023, 1 month.

Results were first posted in Aug 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 6, 2023
StartActual
Jan 27, 2023
Primary completionActual
Mar 15, 2023
CompletionActual
Apr 19, 2023
Results first posted
Aug 16, 2024
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05673889
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Jan 27, 2023
Primary completion
Mar 15, 2023
Completion
Apr 19, 2023
Results posted
Aug 16, 2024
Last update
Aug 16, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion